Tomi Sawyer, Ph.D.Chief Drug Hunter & President at Maestro Therapeutics
Tomi is Founding Chief Drug Hunter and President of Maestro Therapeutics. Previously, Tomi was a Distinguished Scientist, Merck & Company, Founding Chief Scientific Officer at Aileron Therapeutics and Senior Vice-President of Drug Discovery at Ariad Pharmaceuticals (now Takeda). He is a peptide, peptidomimetic, de novo nonpeptide, small molecule and natural product drug hunter and has contributed to the discovery of three marketed drugs (Scenesse®, Iclusig® and Ridaforolimus), a Phase II clinical candidate (ALRN-6924) and past preclinical development of renin inhibitors, HIV protease inhibitors, Src SH2 antagonists and dual Src/Bcr-Abl kinase inhibitors. Tomi is credited with >600 scientific publications, patents, and presentations.